Collaborative Management Between Dermatologists and Pediatricians of a 3-Year-Old Boy with Atopic Dermatitis-Related Sleep Disturbance and Reduced Quality of Life Using Dupilumab: A Case Report
Abstract
A 3-year-old boy presented with recurrent eczema that began at 2 months of age. The patient was treated by multiple dermatologists using topical steroids, topical immunosuppressants, and oral antihistamines. The patient was subsequently referred to our clinic for improved symptom control. During the initial visit, he exhibited serous erythema, scaling, and scratch marks on the scalp, face, and limbs. Laboratory findings revealed elevated levels of immunoglobulin E at 5400 IU/mL, thymus and activation-regulated chemokine at 3029 pg/mL, and an Eczema Area and Severity Index score of 16. Due to sleep disturbances caused by nocturnal itching and substantially reduced quality of life, we initiated treatment with dupilumab. A pediatrician conducted pre-treatment assessments, including blood tests and chest radiography. Following the initiation of dupilumab therapy, the pediatrician monitored the patient for potential reactions and side effects, and the dermatologist managed the skin symptoms. This case underscores the importance of interdisciplinary collaboration between pediatrics and dermatology in managing severe eczema in young children treated with dupilumab.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.